Introduction: The aim of our survey was to evaluate the usage and indications of various metastatic prostate cancer (PCa) therapies, and to identify barriers to usage of bisphosphonates (BPs). Materials and Methods: Between March and June 2009, an internet-based survey was performed among board-certified urologists of the EAU who treated ≥10 patients with metastatic PCa annually. Results: Questionnaires completed by 200 urologists from 12 European countries including 27,442 PCa patients were used for analyses. On average, 22% of the patients presented in stage IV, 15% had bone metastases and 10% received BPs. In most countries, BPs were used to the same extent in hormone-naïve and castration-resistant PCa (CRPC). A total of 23% of urologists prescribed chemotherapy in patients with hormone-sensitive PCa, and 55% of the urologists did not administer androgen deprivation maintenance therapy in patients with CRPC. Conclusions: BPs were frequently used in PCa with bone metastases, although current guidelines recommend their use only in CRPC. Standardized multidisciplinary educational programs should be developed in order to prevent non-indicated early chemotherapy in hormone-sensitive patients and to stimulate maintenance of androgen deprivation therapy in CRPC patients. Also, programs facilitating home infusions for patients who need intravenous BPs are needed in specific countries to optimize treatment of CRPC.

Keywords:
Castration-resistant prostate cancer, Bone metastasis, Androgen deprivation, Europe, Osteonecrosis of the jaw, Renal insufficiency, Zoledronic acid, Ibandronate, Clodronate
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.
2.
Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F, European Association of Urology. EAU guidelines on prostate cancer. Eur Urol 2008;53:68–80.
3.
Weinfurth KP, Li Y, Castel LD, et al: The significance of skeletal-related events for the health related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16:579–584.
4.
Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R: Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007;110:1860–1867.
5.
Janjan N: Bone metastases: approaches to management. Semin Oncol 2001;28(suppl 11):28–34.
6.
Yau V, Chow E, Davis L, et al: Pain management in cancer patients with bone metastases remains a challenge. J Pain Symptom Manage 2004;27:1–3.
7.
Miaskowski C, Dodd MJ, West C, Paul SM, Tripathy D, Koo P, Schumacher K: Lack of adherence with the analgesic regime: a significant barrier to effective cancer pain management. J Clin Oncol 2001;19:4275–4279.
8.
Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584–593.
9.
Saad F, Gleason DM, Murray R, et al: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458–1468.
10.
Nørgaard M, Jensen AØ, Jacobsen JB, Cetin K, Fryzek JP, Sørensen HT: Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 2010;184:162–167.
11.
Lipton A: Implications of bone metastases and the benefits of bone-targeted therapy. Semin Oncol 2010;37(suppl 2):S15–S29.
12.
Dearnaley DP, Mason MD, Parmar MK, Sanders K, Sydes MR: Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and MRC PR05 randomised controlled trials. Lancet Oncol 2009;10:872–876.
13.
Heidenreich A, Elert A, Hofmann R: Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 2002;5:231–235.
14.
Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO: Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003;21:4277–4284.
15.
O’Rourke N, McCloskey E, Houghton F, Huss H, Kanis JA: Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases. J Clin Oncol 1995;13:929–934.
16.
Ernst DS, MacDonald RN, Paterson AH, Jensen J, Brasher P, Bruera E: A double-blind, crossover trial of intravenous clodronate in metastatic bone pain. J Pain Symptom Manage 1992;7:4–11.
17.
Heidenreich A, Hofmann R, Engelmann UH: The use of bisphosphonates for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 2001;165:136–140.
18.
Gálvez R, Ribera V, González-Escalada JR, Souto A, Cánovas ML, Castro A, Herrero B, de Los Angeles Maqueda M, Castilforte M, Marco-Martínez JJ, Pérez C, Vicente-Fatela L, Md CN, Orduña MJ, Padrol A, Reig E, Carballido J, Cózar JM: Analgesic efficacy of zoledronic acid and its effect on functional status of prostate cancer patients with metastasis. Patient Prefer Adherence 2008;2:215–224.
19.
National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology™: Prostate Cancer. www.nccn.org/professionals/physician_gls/PDF/prostate.pdf.
20.
British Association of Urological Surgeons. Metastatic prostate cancer guidelines. www.echurology.co.uk/baus.html.
21.
Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE, Paszat L: Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol 2010;184:918–923.
22.
Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR: Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol 2010;183:2200–2205.
23.
Campbell SC, Bhoopalam N, Moritz TE, Pandya M, Iyer P, Vanveldhuizen P, Ellis NK, Thottapurathu L, Garewal H, Warren SR, Friedman N, Reda DJ: The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis. Urology 2010;75:1138–1143.
24.
Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV: Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 2006;176:972–978.
25.
Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, Van Veldhuizen PJ, Friedman N, Reda D, Warren S, Garewal H: Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. J Urol 2009;182:2257–2264.
26.
Satoh T, Kimura M, Matsumoto K, Tabata K, Okusa H, Bessho H, Iwamura M, Ishiyama H, Hayakawa K, Baba S: Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma. Cancer 2009;115:3468–3474.
27.
Lipton A: Emerging role of bisphosphonates in the clinic – antitumor activity and prevention of metastasis to bone. Cancer Treat Rev 2008;34(suppl 1):S25–S30.
28.
Weitzman R, Sauter N, Eriksen EF, et al: Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients. Crit Rev Oncol Hematol 2007;62:148–152.
29.
Mehrotra B: Safety profiles of intravenous bisphosphonates. Semin Oncol 2007;34 (suppl 4):S24–S27.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.